The IGF system and breast cancer

Endocrine-Related Cancer

Volumn 8, Issue 3, 2001, Pages 197-209

  Sachdev, D ^a   Yee, D ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; ESTROGEN RECEPTOR; PROTEIN IRS 1; SOMATOMEDIN; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C; SOMATOMEDIN RECEPTOR; UNCLASSIFIED DRUG;

APOPTOSIS; BREAST CARCINOGENESIS; BREAST CARCINOMA; BREAST EPITHELIUM; CANCER GROWTH; CANCER RESEARCH; CELL PROLIFERATION; CONFERENCE PAPER; HUMAN; MITOSIS; NONHUMAN; PROTEIN FAMILY; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

BREAST NEOPLASMS; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II;

EID: 0034788985     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0080197     Document Type: Conference Paper

References (157)

1. Growth factors and cancer
2. Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice
3. Role of insulin-like growth factors in embryonic and postnatal growth
4. The IGF-IR receptor in normal and abnormal growth
5. Mammary cancer in transgenic mice expressing insulin-like growth factor II (IGF-II)
6. Recommendations for nomenclature of the insulin-like growth factor binding protein superfamily
7. The proto-oncogene product c-Crk associates with insulin receptor substrate-1 and 4PS. Modulation by insulin growth factor-I (IGF) and enhanced IGF-I signaling
8. Sporadic amplification of the insulin-like growth factor 1 receptor gene in human breast tumors
9. Effect of endocrine therapy on growth of T61 human breast cancer xenografts is directly correlated to a specific down-regulation of insulin-like growth factor II (IGF-II)
10. The T61 human breast cancer xenograft: An experimental model of estrogen therapy of breast cancer
11. Down-regulation of T1A12/mac25, a novel insulin-like growth factor binding protein related gene, is associated with disease progression in breast carcinomas
12. Regulation of progesterone receptor gene expression in MCF-7 breast cancer cells: A comparison of the effects of cyclic adenosine 3′,5′-monophosphate, estradiol, insulin-like growth factor-I, and serum factors
13. Nutritional regulation of IGF-I and IGF binding proteins
14. Modifications of insulin-like growth factor binding proteins and their role in controlling IGF actions
15. Insulin-like growth factor receptor expression and function in human breast cancer
16. A soluble insulin-like growth factor I receptor that induces apoptosis of tumor cells in vivo and inhibits tumorigenesis
17. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
18. 14-3-3 Proteins and survival kinases cooperate to inactivate BAD by BH3 domain phosphorylation
19. Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations
20. A growth-deficiency phenotype in heterozygous mice carrying an insulin-like growth factor II gene disrupted by targeting
21. Distribution of IGFBP-rP1 in normal human tissues
22. The roles of integrins and extracellular matrix proteins in the insulin-like growth factor I-stimulated chemotaxis of human breast cancer cells
23. Mitogenic signaling of insulin-like growth factor I in MCF-7 human breast cancer cells requires phosphatidylinositol 3-kinase and is independent of mitogen-activated protein kinase
24. Insulin-like growth factor I (IGF-I) alters drug sensitivity of HBL100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs
25. A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer
26. The insulin-like growth factor-1 elevates urokinase-type plasminogen activator-1 in human breast cancer cells: A new avenue for breast cancer therapy
27. Distribution of insulin/insulin-like growth factor-I hybrid receptors in human tissues
28. Evidence that the growth hormone receptor mediates differentiation and development of the mammary gland
29. Recombinant insulin-like growth factor binding protein-1 inhibits IGF-I, serum, and estrogen-dependent growth of MCF-7 human breast cancer cells
30. Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer
31. Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells
32. IGF-II mRNA and protein are expressed in the stroma of invasive breast cancers: An in situ hybridization and immunohistochemistry study
33. Involvement of Src-homology/collagen (SHC) proteins in signaling through the insulin receptor and the insulin-like-growth-factor-I-receptor
34. Interleukin 4 inhibits growth and induces apoptosis in human breast cancer cells
35. Insulin-like growth factor (IGF)-I rescues breast cancer cells from chemotherapy-induced cell death - Proliferative and anti-apoptotic effects
36. Insulin-like growth factor binding protein 3 mediates retinoic acid- and transforming growth factor beta2-induced growth inhibition in human breast cancer cells
37. Overexpressed IGF-I receptors reduce estrogen growth requirements, enhance survival, and promote E-cadherin-mediated cell-cell adhesion in human breast cancer cells
38. Targeted expression of des(1-3) human insulin-like growth factor I in transgenic mice influences mammary gland development and IGF-binding protein expression
39. Cooperative interaction between mutant p53 and des(1-3)IGF-I accelerates mammary tumorigenesis
40. M6P/IGF2 receptor: A candidate breast tumor suppressor gene
41. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer
42. Interaction of insulin receptor substrate-2 (IRS-2) with the insulin and insulin-like growth factor I receptors. Evidence for two distinct phosphotyrosine-dependent interaction domains within IRS-2
43. Mutational analysis of the mitogenic and transforming activities of the insulin-like growth factor I receptor
44. Characterization of insulin-like growth factor-binding protein-related protein-1 in prostate cells
45. The insulin-like growth factor-binding protein (IGFBP) superfamily
46. Insulin receptor substrate-1 is the predominant signaling molecule activated by insulin-like growth factor-I, insulin, and interleukin-4 in estrogen receptor-positive human breast cancer cells
47. Elevated levels of p66 She are found in breast cancer cell lines and primary tumors with high metastatic potential
48. Nuclear localization of insulin-like growth factor binding protein 3 in a lung cancer cell line
49. Insulin-like growth factor binding protein 1 stimulates cell migration and binds to the alpha 5 beta 1 integrin by means of its Arg-Gly-Asp sequence
50. Cell migration: Interactions among integrins, IGFs and IGFBPs
51. Differential responsiveness of human breast cancer cell lines MCF-7 and T47D to growth factors and 17 beta-estradiol
52. Multihormonal regulation of the progesterone receptor in MCF-7 human breast cancer cells: Interrelationships among insulin/insulin-like growth factor-I, serum, and estrogen
53. An alternative to SH2 domains for binding tyrosine-phosphorylated proteins
54. Identification of a family of low-affinity insulin-like growth factor binding proteins (IGFBPs): Characterization of connective tissue growth factor as a member of the IGFBP superfamily
55. Non-lactogenic effects of growth hormone on growth and insulin-like growth factor-I messenger ribonucleic acid of rat mammary gland
56. IGF-I: An essential factor in terminal end bud formation and ductal morphogenesis
57. Akt-dependent and -independent survival signaling pathways utilized by insulin-like growth factor I
58. Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt
59. Insulin-like growth factors and breast cancer
60. Processing of insulin-like growth factor-II (IGF-II) by human breast cancer cells
61. Enhancement of insulin-like growth factor signaling in human breast cancer: Estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo
62. Insulin-like growth factor I-induced degradation of insulin receptor substrate 1 is mediated by the 26S proteasome and blocked by phosphatidylinositol 3′-kinase inhibition
63. Nck associates with the SH2 domain-docking protein IRS-1 in insulin-stimulated cells
64. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igflr)
65. Interactions between Ras and Raf: Key regulatory proteins in cellular transformation
66. Regulation of insulin-like growth factor-binding protein (IGFBP) expression by breast cancer cells: Use of IGFBP-1 as an inhibitor of insulin-like growth factor action
67. Insulin receptor expression and function in human breast cancer cell lines
68. Paracrine actions of IGF binding proteins
69. Effect of a mutation at tyrosine 950 of the insulin-like growth factor I receptor on the growth and transformation of cells
70. Different effects on mitogenesis and transformation of a mutation at tyrosine 1251 of the insulin-like growth factor I receptor
71. Insulin receptor substrate-1 expression is regulated by estrogen in the MCF-7 human breast cancer cell line
72. Insulin-like growth factor II receptor as a multifunctional binding protein
73. Insulin-like growth factor II stimulates cell proliferation through the insulin receptor
74. Identification and characterization of genes differentially expressed in meningiomas
75. Insulin receptor substrate-1 mediates phosphatidylinositol 3′-kinase and p70S6k signaling during insulin, insulin-like growth factor-1, and interleukin-4 stimulation
76. The IRS-1 signaling system
77. YMXM motifs and signaling by an insulin receptor substrate 1 molecule without tyrosine phosphorylation sites
78. Growth inhibition of MCF-7 breast cancer cells by stable expression of an insulin-like growth factor I receptor antisense ribonucleic acid
79. Involution of the lactating mammary gland is inhibited by the IGF system in a transgenic mouse model
80. Differential roles of IRS-1 and SHC signaling pathways in breast cancer cells
81. The mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R), a putative breast tumor suppressor gene
82. Identification of domains of the insulin-like growth factor I receptor that are required for protection from apoptosis
83. 14-3-3 Protein binds to insulin receptor substrate-1, one of the binding sites of which is in the phosphotyrosine binding domain
84. Tamoxifen in the treatment of breast cancer
85. Insulin-like growth factor-II (IGF-II): A potential autocrine/paracrine growth factor for human breast cancer acting via the IGF-I receptor
86. Expression of IGF-I and IGF-II mRNA in breast tissue
87. Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: Evidence for a second mechanism of IGF-I signaling
88. Elevated insulin receptor content in human breast cancer
89. Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer
90. Insulin-like growth factor-I inhibition of apoptosis is associated with increased expression of the bcl-xL gene product
91. Insulin-like growth factor I inhibits apoptosis using the phosphatidylinositol 3′-kinase and mitogen-activated protein kinase pathways
92. The role of insulin-like growth factors in prostate biology
93. Receptors for epidermal growth factor and insulin-like growth factor I and their relation to steroid receptors in human breast cancer
94. A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction
95. Multiple signaling pathways of the insulin-like growth factor I receptor in protection from apoptosis
96. Type 1 IGF receptor in human breast diseases
97. Insulin-like growth factor I receptors in human breast cancer and their relation to estradiol and progesterone receptors
98. Insulin-like growth factor-I (IGF-I) receptors in breast cancer
99. Endocrine effects of IGF-I on normal and transformed breast epithelial cells: Potential relevance to strategies for breast cancer treatment and prevention
100. Presence of somatomedin receptors on primary human breast and colon carcinomas
101. Effect of tamoxifen on serum insulin-like growth factor I levels in stage I breast cancer patients
102. IGF-I is required for normal embryonic growth in mice
103. Insulin receptor substrate-4 enhances insulin-like growth factor-I-induced cell proliferation
104. The prognostic value of insulin-like growth factor-I in breast cancer patients. Results of a follow-up study on 126 patients
105. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta1 on programmed cell death through a p53- and IGF-independent mechanism
106. Paracrine/autocrine regulation of breast cancer by the insulin-like growth factors
107. The effect of endocrine therapy with medroxyprogesterone acetate, 4-hydroxyandrostenedione or tamoxifen on plasma concentrations of insulin-like growth factor (IGF)-I, IGF-II and IGFBP-1 in women with advanced breast cancer
108. Elevated insulin-like growth factor I receptor autophosphorylation and kinase activity in human breast cancer
109. Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: Correlation with clinical parameters and disease-free survival
110. Structure, evolution, expression and regulation of insulin-like growth factors I and II
111. Insulin-like growth factor I is essential for terminal end bud formation and ductal morphogenesis during mammary development
112. Intact and amino-terminally shortened forms of insulin-like growth factor I induce mammary gland differentiation and development
113. Estradiol enhances the stimulatory effect of insulin-like growth factor- I (IGF-I) on mammary development and growth hormone-induced IGF-I messenger ribonucleic acid
114. Insulin-like growth factor-I receptor. Its role in cell proliferation, apoptosis, and tumorigenicity
115. Insulin receptor substrate 1 is a target for the pure antiestrogen ICI 182,780 in breast cancer cells
116. Insulin-like growth factor-binding protein (1GFBP)-3 and IGFBP-5 share a common nuclear transport pathway in T47D human breast carcinoma cells
117. Nuclear import of insulin-like growth factor-binding protein-3 and -5 is mediated by the importin beta subunit
118. Insulin receptor activation by IGF-II in breast cancers: Evidence for a new autocrine/paracrine mechanism
119. Structure and function of the insulin-like growth factor I receptor
120. Identification and molecular characterization of insulin-like growth factor binding proteins (IGFBP-1, -2, -3, -4, -5 and -6)
121. Malignant breast epithelium selects for insulin-like growth factor II expression in breast stroma: Evidence for paracrine function
122. Type I insulin-like growth factor receptor activation regulates apoptotic proteins
123. The function of GRB2 in linking the insulin receptor to Ras signaling pathways
124. The SH2/SH3 domain-containing protein GRB2 interacts with tyrosine-phosphorylated IRS1 and Shc: Implications for insulin control of ras signalling
125. Purified hybrid insulin/insulin-like growth factor-I receptors bind insulin-like growth factor-I, but not insulin, with high affinity
126. Insulin-like growth factor binding protein-related protein 1 (IGFBP-rP1) is a potential tumor suppressor protein for prostate cancer
127. Modulation of the proliferative response of breast cancer cells to growth factors by oestrogen
128. Pleiotropic insulin signals are engaged by multisite phosphorylation of IRS-1
129. Enhanced expression of an insulin growth factor-like binding protein (mac25) in senescent human mammary epithelial cells and induced expression with retinoic acid
130. A carboxy-terminal truncated insulin receptor substrate-1 dominant negative protein reverses the human hepatocellular carcinoma malignant phenotype
131. Evidence for a differential interaction of SHC and the insulin receptor substrate-I (IRS-I) with the insulin-like growth factor-I (IGF-I) receptor in the yeast two-hybrid system
132. Interaction of the molecular weight 85K regulatory subunit of the phosphatidylinositol 3-kinase with the insulin receptor and the insulin-like growth factor-I (IGF- I) receptor: Comparative study using the yeast two-hybrid system
133. Interaction of the alpha beta dimers of the insulin-like growth factor I receptor is required for receptor autophosphorylation
134. The mitogen-activated protein (MAP) kinase cascade can either stimulate or inhibit DNA synthesis in primary cultures of rat hepatocytes depending upon whether its activation is acute/phasic or chronic
135. Expression of insulin-like growth factor II in female breast cancer as related to established prognostic factors and long-term prognosis
136. Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation
137. Insulin-like growth factor I receptor primary structure: Comparison with insulin receptor suggests structural determinants that define functional specificity
138. Estrogen regulation of the insulin-like growth factor I gene transcription involves an AP-1 enhancer
139. The human insulin-like growth factor (IGF) binding protein-3 inhibits the growth of fibroblasts with a targeted disruption of the IGF-I receptor gene
140. Anterior pituitary development: Short tales from dwarf mice
141. Association of insulin receptor substrate-1 with integrins
142. Evidence that the mammary fat pad mediates the action of growth hormone in mammary gland development
143. Disproportionate growth in mice with Igf-2 transgenes
144. Repression of the insulin receptor promoter by the tumor suppressor gene product p53: A possible mechanism for receptor overexpression in breast cancer
145. Somatostatin analogue octreotide enhances the antineoplastic effects of tamoxifen and ovariectomy on 7,12-dimethyl-benz(alpha)anthracene-induced rat mammary carcinomas
146. The insulin-like growth factor receptor: Molecular biology, heterogeneity, and regulation
147. Relaxation of imprinting of human insulin-like growth factor II gene, IGF2, in sporadic breast carcinomas
148. Normal growth and development in the absence of hepatic insulin-like growth factor I
149. Reduced growth of human breast cancer xenografts in hosts homozygous for the lit mutation
150. Imprinting and expression of insulin-like growth factor-II and H19 in normal breast tissue and breast tumor
151. The insulin-like growth factors and breast cancer - Revisited
152. Crosstalk between the insulin-like growth factors and estrogens in breast cancer
153. Insulin-like growth factor II mRNA expression in human breast cancer
154. Analysis of insulin-like growth factor I gene expression in malignancy: Evidence for a paracrine role in human breast cancer
155. Insulin-like growth factor binding protein 1 expression inhibits insulin-like growth factor I action in MCF-7 breast cancer cells
156. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L)
157. Insulin-like growth factor I-mediated degradation of insulin receptor substrate-1 is inhibited by epidermal growth factor in prostate epithelial cells